Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers

Elkasabgy, Nermeen A.; Adel, Islam

doi:10.1208/s12249-020-01757-2

Cited by 21 publications

(14 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the solid-based delivery aerosol systems (i.e., DPIs) can overcome the previously mentioned drawbacks of nebulizers as they have many advantages and unique features [ 69 ]. They are easy to use, can be self-administered, portable, do not need hospitalization, cost-effective, and can efficiently deliver high doses of anticancer drugs or drug-loaded nanocarriers as dry powder to the lungs [ 70 ].…”

Section: Devices For the Pulmonary Drug Delivery Of Anticancer Drug-loaded Lipid-based Nanocarriersmentioning

confidence: 99%

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

et al. 2021

View full text Add to dashboard Cite

Lung cancer (LC) is the leading cause of cancer-related deaths, responsible for approximately 18.4% of all cancer mortalities in both sexes combined. The use of systemic therapeutics remains one of the primary treatments for LC. However, the therapeutic efficacy of these agents is limited due to their associated severe adverse effects, systemic toxicity and poor selectivity. In contrast, pulmonary delivery of anticancer drugs can provide many advantages over conventional routes. The inhalation route allows the direct delivery of chemotherapeutic agents to the target LC cells with high local concertation that may enhance the antitumor activity and lead to lower dosing and fewer systemic toxicities. Nevertheless, this route faces by many physiological barriers and technological challenges that may significantly affect the lung deposition, retention, and efficacy of anticancer drugs. The use of lipid-based nanocarriers could potentially overcome these problems owing to their unique characteristics, such as the ability to entrap drugs with various physicochemical properties, and their enhanced permeability and retention (EPR) effect for passive targeting. Besides, they can be functionalized with different targeting moieties for active targeting. This article highlights the physiological, physicochemical, and technological considerations for efficient inhalable anticancer delivery using lipid-based nanocarriers and their cutting-edge role in LC treatment.

show abstract

Section: Devices For the Pulmonary Drug Delivery Of Anticancer Drug-loaded Lipid-based Nanocarriersmentioning

confidence: 99%

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Upon actuation of the valve, a sudden reduction in external pressure prompts rapid evaporation of the propellants, leading to the aerosolization and delivery of the drugs. [13] In liquid systems, protein drugs necessitate the formation of hydrogen or ionic bonds with the dispersion medium to maintain a highly dispersed state. Within pMDIs, propellants serve as the primary components and act as dispersion media for protein drugs.…”

Section: Pressurized Metered-dose Inhaler (Pmdi) Is a Highly Promisin...mentioning

confidence: 99%

Lecithin Reverse Micelle System is Promising in Constructing Carrier Particles for Protein Drugs Encapsulated Pressurized Metered‐Dose Inhalers

Chang

Wang

Huang

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Protein drugs contained within pressurized metered dose inhalers (pMDIs) show immense potential for fundamental research and industrial applications, owing to their high bioavailability, convenient administration, and cost‐effectiveness. To deliver protein drugs efficiently, researchers have reached a consensus on the use of carrier particles. However, the main obstacle impeding the commercial availability of pMDI carrier particles is their low stability. This instability is primarily attributed to particle aggregation caused by the Ostwald ripening phenomenon and chemical degradation by water sensitivity of protein drugs. This study proposes the utilization of lecithin, a carrier material possessing an amphiphilic structure, to overcome this bottleneck. By constructing lecithin‐based reverse micelle systems with protein drugs encapsulated within the high‐polarity microdomain, this work anticipates an improvement in the stability of carrier particles within pMDIs. Specifically, the formation of crystalline phases in the reverse micelle systems can control carrier particle size through crystalline self‐limiting effect, preventing particle aggregation. Additionally, the low‐polarity microdomain of the carrier serves as a hydrophobic barrier, shielding protein drugs from water and preventing chemical degradation. Consequently, this work believes that the lecithin‐based reverse micelle system holds significant potential in providing new theoretical insights and experimental support for the advancement of pMDIs containing protein drugs.

show abstract

“…Such patterns strongly influence the resulting inhaled drug pharmacokinetics (PK) as a consequence of the known dependency of the drug’s fate on the actual deposition site along the respiratory tract. A thorough discussion of such aspects is beyond the scope of this review, and readers can refer to the work of EIKasabgy et al for more details [ 11 ]. In order to reach the lower respiratory tract and optimize pulmonary drug delivery, particle aerodynamic diameter should span between 0.5 μm and 5 μm [ 12 , 13 ].…”

Section: State Of the Artmentioning

confidence: 99%

Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives

et al. 2021

View full text Add to dashboard Cite

During the last decades, the term “drug delivery systems” (DDSs) has almost fully replaced previously used terms, such as “dosage forms”, in an attempt to emphasize the importance of the drug carrier in ensuring the claimed safety and effectiveness of the product. However, particularly in the case of delivery devices, the term “system”, which by definition implies a profound knowledge of each single part and their interactions, is not always fully justified when using the DDS term. Within this context, dry powder inhalers (DPIs), as systems to deliver drugs via inhalation to the lungs, require a deep understanding of the complex formulation–device–patient interplay. As of now and despite the progress made in particle engineering and devices design, DPIs’ clinical performance is limited by variable patients’ breathing patterns. To circumvent this pitfall, next-generation DPIs should ideally adapt to the different respiratory capacity of individuals across age, health conditions, and other related factors. In this context, the recent wave of digitalization in the health care and industrial sectors may drive DPI technology towards addressing a personalized device–formulation–patient liaison. In this review, evolving technologies are explored and analyzed to outline the progress made as well as the gaps to fill to align novel DPIs technologies with the systems theory approach.

show abstract

Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers

Cited by 21 publications

References 108 publications

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update

Lecithin Reverse Micelle System is Promising in Constructing Carrier Particles for Protein Drugs Encapsulated Pressurized Metered‐Dose Inhalers

Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives

Contact Info

Product

Resources

About